U.S. Life Sciences Stock News

Marriott Vacations Worldwide (NYSE:VAC) recorded about $546 million in non-cash impairments tied to asset write downs and goodwill linked to earlier acquisitions. The company is reshaping its priorities toward profitability and free cash flow, including deferred or cancelled projects in Asia and fewer Asia Pacific tours planned for 2026. Leadership changes include Matt Avril stepping in as CEO and Mike Flaskey as President, signaling a new direction for the vacation ownership business. For...

Lineage, Inc. reported fourth-quarter 2025 sales of US$1,336 million, essentially flat year on year, but moved from a US$71 million net loss to a US$6 million net profit, with basic and diluted earnings per share from continuing operations improving from a loss of US$0.33 to earnings of US$0.03. For 2025 as a whole, Lineage’s sales edged up to US$5,355 million while its net loss narrowed sharply from US$664 million to US$100 million, indicating materially improved cost control and...

If you are wondering whether Sonic Automotive's current share price gives you genuine value, it helps to break the story into what the stock has done recently and what the fundamentals say about it. The shares most recently closed at US$62.62, with returns of 4.4% over 30 days, 1.6% year to date, a 3.2% decline over 1 year, 13.5% over 3 years and 38.0% over 5 years. Recent coverage around Sonic Automotive has focused on its position as a US auto retailer and how investors are weighing that...

Versant Media Group (NasdaqGS:VSNT) authorized a new $1b share repurchase program. The company declared a quarterly cash dividend, initiating regular capital returns to shareholders. Management highlighted recent acquisitions and progress in building Versant as a standalone public company. Versant Media Group, trading at $34.01 per share, is moving ahead with a mix of buybacks, dividends, and acquisitions that directly affect how capital is used. The stock is up 13.9% over the past week and...

If you are wondering whether Fortune Brands Innovations is fairly priced or offering hidden value at its current level, this article is designed to walk you through the key signals step by step. The stock recently closed at US$51.38, with returns of an 8.6% decline over 7 days, a 5.0% decline over 30 days, a 0.9% gain year to date, and a 14.4% decline over 1 year, plus longer term declines of 10.6% over 3 years and 26.0% over 5 years. Recent coverage has focused on how the share price...

Event context and recent share performance G-III Apparel Group (GIII) has drawn investor attention after a recent move in its share price, with the stock showing a small 1 day decline but gains over the month and past 3 months. Over the past year, GIII has delivered a total return of about 20%. The 3 year total return is very large at roughly 8x, in contrast with a 4% decline over 5 years. This mixed performance record may prompt investors to reassess expectations. See our latest analysis for...

SkyWater Technology (SKYT) has drawn fresh attention after reporting fourth quarter and full year 2025 results, with quarterly sales of US$171.04 million and a full year swing to net income of US$118.92 million. See our latest analysis for SkyWater Technology. The latest earnings update has come alongside a sharp shift in sentiment, with a 90 day share price return of 63.11% and a 1 year total shareholder return of 245.89%. This suggests momentum has built quickly despite a recent 5.72% 30...

Vir Biotechnology (VIR) is back in focus after its agreement with Astellas Pharma on prostate cancer candidate VIR-5500, along with fresh Phase 1 data and several recent equity financing moves. See our latest analysis for Vir Biotechnology. Despite a 4.6% 1-day share price decline to US$8.91 and some pressure over the past week, Vir Biotechnology’s roughly 20% 1-month and 42% 3-month share price returns suggest momentum has picked up around the Astellas partnership, Phase 1 VIR-5500 data and...

If you are wondering whether Dow's share price still reflects good value, the recent mix of gains and setbacks makes it an interesting name to look at closely. The stock trades at US$30.74, with a 1% decline over the last 7 days, an 11.6% gain over 30 days, a 26.7% gain year to date, and returns of a 7.9% decline over 1 year, a 34.2% decline over 3 years, and a 35.1% decline over 5 years. Recent coverage around Dow has focused on its role as a large materials company and its exposure to...

If you are wondering whether Marriott International's current share price offers fair value, this is a closer look at what the market might be pricing in. The stock recently closed at US$335.91, with returns of 6.5% over the last 30 days, 7.2% year to date, and longer term returns of 25.2% over 1 year, 99.4% over 3 years, and 137.4% over 5 years, which may influence how investors view its potential and risk. Recent news flow around Marriott International has focused on broader themes such as...

In recent weeks, Ameriprise Financial has faced insider share sales by several top executives, the planned retirement of a key Advice & Wealth Management leader, and an SEC fine related to compliance failures involving unapproved electronic messaging platforms. At the same time, its Columbia Threadneedle asset management arm was ranked by Barron's among the top fund families across 1-, 5-, and 10-year periods, underscoring the group’s long-term investment performance. We’ll examine how the...

Event context and recent share performance Arthur J. Gallagher (AJG) has been drawing attention after a period of mixed share performance, with the stock showing gains over the past week but declines over the past month, past 3 months, year to date, and past year. In this context, some investors are reassessing how the company’s current share price of $225.23 and its recent return profile align with its scale, with reported revenue of $13.0b and net income of $1.5b. See our latest analysis...

Pinnacle West Capital (PNW) has drawn fresh attention after recent share price moves, with the stock last closing at $102. Investors are weighing this level against the company’s fundamentals and recent return profile. See our latest analysis for Pinnacle West Capital. The recent move to a $102 share price sits within a stronger trend, with a 30 day share price return of 9.02% and a year to date share price return of 15.72%, alongside a 5 year total shareholder return of 63.94%. Together,...

Core Scientific (CORZ) just posted its FY 2025 Q4 numbers, reporting revenue of US$79.8 million, basic EPS of US$0.68 and net income of US$216.0 million. The company has seen quarterly revenue move in a tight band between US$78.6 million and US$95.4 million since late 2024, while basic EPS has swung from a loss of US$1.17 per share in 2024 Q3 to a profit of US$0.68 in 2025 Q4, highlighting how volatile margins have been for shareholders tracking the story. With trailing twelve month EPS still...

If you are wondering whether Church & Dwight is offering fair value at its current share price, you are not alone. This article is built to help you assess what you are really paying for. The stock last closed at US$103.02, with a 7.0% return over the past 30 days, a 24.7% return year to date, but a 5.7% decline over the past year and longer term returns of 27.6% over 3 years and 35.9% over 5 years. Recent interest in Church & Dwight reflects its position as a long established household...

Wondering whether Stoke Therapeutics at around US$33.78 is starting to look expensive or if there is still value on the table? This article walks through the key numbers so you can judge for yourself. The stock has been volatile, with a 4.8% decline over the last 7 days, an 11.3% gain over 30 days, a 9.3% return year to date, a 345.6% return over 1 year, a 266.0% return over 3 years, and a 34.9% decline over 5 years. These price swings sit against a backdrop of ongoing attention on Stoke...

Formula One Group (FWON.K) is back on investors’ radar after year-end results showed higher revenue and a return to profit, alongside a fresh five-year Concorde Agreement and expanded global media partnerships. See our latest analysis for Formula One Group. At a share price of US$88.81, Formula One Group has given investors a 1-year total shareholder return decline of 2.5%, although the 3-year and 5-year total shareholder returns of 28.2% and 100.5% suggest longer term holders have seen...

CACI International (NYSE:CACI) has announced and priced a $500 million senior notes offering. The company plans to use the proceeds to help fund its acquisition of ARKA Group L.P. The transaction affects CACI International's capital structure and future debt obligations. For investors watching NYSE:CACI, this new senior notes offering comes at a time when the stock is trading at $629.75. The shares show longer term returns of 78.4% over the past year, 110.5% over three years, and 182.1%...

If you are wondering whether Palantir Technologies' current share price still makes sense after everything that has happened with the stock, this article will walk you through what the current market price could be implying about its value. The stock closed at US$147.22, with returns of 9.7% over the last 7 days, a 0.4% decline over 30 days, a 12.3% decline year to date, 63.3% over 1 year, and a very large gain over 3 years, which naturally raises questions about how much optimism is already...

Conference appearance puts U.S. Gold in focus U.S. Gold (USAU) is set to present at the Emerging Growth Virtual Conference on February 25, 2026. Executive Chairman Luke Anthony Norman is expected to speak, drawing attention to potential commentary on projects and capital needs. See our latest analysis for U.S. Gold. At a share price of US$18.84, U.S. Gold has seen a 7 day share price return of 4.96% and a 30 day share price return of 8.65%. The 1 year total shareholder return of 125.90% and 3...

Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. This approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments. Next, we’ll examine...

If you are wondering whether Ross Stores is still good value after its run in the market, it helps to separate the share price story from what the underlying business may be worth. The stock last closed at US$197.64, with a 1.5% decline over 7 days, a 4.8% gain over 30 days, and returns of 8.2% year to date, 47.0% over 1 year, 85.9% over 3 years, and 67.2% over 5 years. This naturally raises questions about what is already priced in. Recent coverage around Ross Stores has largely focused on...

Axos Financial (AX) has been in focus after higher than expected inflation data raised doubts about near term rate cuts, putting pressure on bank stocks and sharpening investor attention on interest rate risk. See our latest analysis for Axos Financial. Despite the inflation driven sell off that recently hit Axos Financial, the current US$89.97 share price sits above its 90 day level, and the 1 year and 3 year total shareholder returns of 39.92% and 97.82% suggest momentum has been positive...

Why Twilio’s latest earnings and KPN partnership are drawing fresh attention Twilio (TWLO) is back on investors’ radar after fourth quarter results came in ahead of guidance, organic revenue growth impressed analysts, and fresh Buy ratings followed, helped by expanding AI focused products and the new RCS partnership with KPN Netherlands. See our latest analysis for Twilio. At a share price of $123.51, Twilio has seen an 8.48% 7 day share price return but a 10.73% decline year to date. The 1...